N-(2-propanoyloxyethyl)morpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: N-(2-propanoyloxyethyl)morpholine
• 英文别名: Propionsaeure-<2-morpholino-aethylester>；1-morpholin-4-yl-2-propionyloxy-ethane；2-Morpholin-4-ylethyl propanoate
• 化学式: C₉H₁₇NO₃
• 分子量: 187.239
• InChiKey: ZMZGNPLJBBGSHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-吗啉乙醇 、 丙酸 以 甲苯 为溶剂， 以75%的产率得到N-(2-propanoyloxyethyl)morpholine
  参考文献：
  名称：

  Synthesis of N-Substituted Oxazolidines and Morpholines

  摘要：

  一系列N-取代的噁唑烷和吗啉被制备并进行了表征。

  DOI：

  10.1007/s11167-005-0502-x

文献信息

• NEPRILYSIN INHIBITORS
  申请人：SMITH Cameron

  公开号：US20120157386A1

  公开（公告）日：2012-06-21

  In one aspect, the invention relates to compounds having the formula: where R 1 -R 6 , a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

  在一方面，本发明涉及具有以下公式的化合物： 其中R1-R6、a、b和X如说明书所述，或其药用可接受的盐。这些化合物具有中性粒细胞弹性蛋白酶抑制活性。在另一方面，本发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF
  申请人：SAMJIN PHARMACEUTICAL CO., LTD.

  公开号：US20150141409A1

  公开（公告）日：2015-05-21

  Disclosed are a novel rebamipide prodrug, a method for preparing the same, and use thereof. Also, a pharmaceutical composition comprising the novel rebamipide prodrug as an active ingredient is provided. The rebamipide prodrug is increased 25-fold in absorption rate compared to rebamipide itself, and can be applied to the prophylaxis or therapy of gastric ulcer, acute gastritis, chronic gastritis, xerophthalmia, cancer, osteoarthritis, rheumatoid arthritis, or obesity.

  揭示了一种新型的雷巴米特前药，以及其制备方法和用途。此外，提供了一种含有该新型雷巴米特前药作为活性成分的药物组合物。与雷巴米特本身相比，雷巴米特前药的吸收速率增加了25倍，可用于预防或治疗胃溃疡、急性胃炎、慢性胃炎、干眼症、癌症、骨关节炎、类风湿性关节炎或肥胖症。
• [EN] PROSTAGLANDIN PRODUGS AS HYPOTENSIVE AGENTS<br/>[FR] PROMÉDICAMENTS DE PROSTAGLANDINES COMME AGENTS HYPOTENSEURS
  申请人：ALLERGAN INC

  公开号：WO2009146255A1

  公开（公告）日：2009-12-03

  Therapeutic compounds, methods, and compositions are disclosed herein for treating glaucoma and baldness in mammals. The specific compounds are described herein and are modified prostaglandin derivates.

  本文披露了用于治疗哺乳动物青光眼和秃顶的治疗化合物、方法和组合物。具体的化合物在本文中描述，是经过改良的前列腺素衍生物。
• ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：US20210179554A1

  公开（公告）日：2021-06-17

  An onium salt having formula (1) serving as an acid diffusion inhibitor and a chemically amplified resist composition comprising the acid diffusion inhibitor are provided. When processed by lithography, the resist composition exhibits a high sensitivity, and excellent lithography performance factors such as CDU and LWR.

  提供一种具有化学式（1）的醇铵盐，用作酸扩散抑制剂，以及包括该酸扩散抑制剂的化学增强型抗蚀剂组合物。当通过光刻加工时，该抗蚀剂组合物表现出高灵敏度和优异的光刻性能因素，例如CDU和LWR。
• RESIST COMPOSITION AND PATTERNING PROCESS
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：US20200249571A1

  公开（公告）日：2020-08-06

  A resist composition comprising a sulfonium salt having formula (1) as PAG, a base polymer, and an organic solvent, when processed by lithography, has light transmittance, acid diffusion suppressing effect, and excellent lithography performance factors such as DOF, LWR and MEF. A lithography process for forming a resist pattern from the composition is also provided.

  一种抗蚀组合物，包括具有公式（1）作为PAG的磺酸盐、基础聚合物和有机溶剂。在光刻工艺中加工时，该组合物具有光透过率、抑制酸扩散效果和优异的光刻性能因素，例如DOF、LWR和MEF。还提供了一种从该组合物形成抗蚀图案的光刻工艺。